FDA adds boxed warning to multiple sclerosis drugs

The menopausal transition may represent an inflection point for worsening of multiple sclerosis (MS) in women, accordi ...
MS patients who achieve long-term stable disease on disease-modifying therapy may want to stop their medication for varying ...
A new study reveals that people with multiple sclerosis (MS) experience significantly higher rates of mental illness during ...
People with multiple sclerosis (MS) face a significantly higher risk of perinatal mental illness compared to those with other ...
A recent study shows that menopause may worsen Multiple Sclerosis symptoms and accelerate its progression due to a decline in ...
Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.
The study identified gene expression changes which were detected beginning three months after intranasal dosing of foralumab in our ongoing ISPPEA (or expanded access program). Key findings include ...
Mothers with multiple sclerosis (MS) have an elevated incidence and prevalence of peripartum mental illness, accordi ...
The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...
The median wait time between referral and appointment was 34 days, and 18 percent of patients waited more than 90 days, the ...